Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353533 | 0.99 | RARB (0.64) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL7403884 | 0.99 | RARB (0.64) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL12243285 | 0.98 | RARB (0.67) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL2353001 | 0.98 | RARB (0.67) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL2354881 | 0.98 | RARB (0.67) | RARBTP53TSHRSMPD1PLA2G4B | |
| Ammonia Solution, Strong SCHEMBL17822400 | 0.98 | RARB (0.63) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL2354038 | 0.96 | SMPD1 (0.63) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL903875 | 0.90 | SMPD1 (0.61) | RARBTP53TSHRSMPD1CXCR1 | |
| SCHEMBL12243204 | 0.89 | SMPD1 (0.60) | RARBTP53TSHRSMPD1PLA2G4B | |
| SCHEMBL16217721 | 0.89 | SMPD1 (0.60) | RARBTP53TSHRSMPD1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199248-B2 | Process | ASTELLAS PHARMA INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050227914-A1 | New process | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| WO-2004014879-A1 | NEW PROCESS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227914-A1 | New process | CA2, AKR1C3, AGTR2 | RARB 3322/4885TP53 2802/4885TSHR 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.